GSK5764227 (Anti-B7H3 Antibody Drug Conjugate) Monotherapy or in Combination With Dostarlimab in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): a Multiomic Evaluation of Biomarkers of Response and Resistance (BeeHive)
Latest Information Update: 05 May 2026
At a glance
- Drugs Dostarlimab (Primary) ; Risvutatug rezetecan (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms BeeHive
- Sponsors GSK
Most Recent Events
- 29 Apr 2026 Planned End Date changed from 30 Jun 2030 to 1 Mar 2031.
- 29 Apr 2026 Status changed from not yet recruiting to recruiting.
- 18 Feb 2026 New trial record